Daniel Karp's most recent trade in Caleres Inc was a trade of 15,244 Common Stock done . Disclosure was reported to the exchange on June 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Caleres Inc | Daniel L. Karpel | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2026 | 15,244 | 39,443 (0%) | 0% | 0 | Common Stock | |
| Caleres Inc | Daniel L. Karpel | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2026 | 11,433 | 50,876 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 100,166 | 100,166 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 11,338 | 68,491 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 11,338 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 6,715 | 71,652 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 6,715 | 13,432 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.70 per share. | 31 Mar 2026 | 3,554 | 64,937 | - | 5.7 | 20,258 | Common Stock |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.70 per share. | 31 Mar 2026 | 2,105 | 69,547 | - | 5.7 | 11,999 | Common Stock |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2026 | 14,184 | 60,853 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2026 | 14,184 | 14,185 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.84 per share. | 29 Mar 2026 | 4,446 | 57,153 | - | 5.8 | 25,965 | Common Stock |
| Caleres Inc | Daniel L. Karpel | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 22,884 | 24,199 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Purchase of securities on an exchange or from another person at price $ 8.24 per share. | 06 May 2025 | 3,500 | 46,669 | - | 8.2 | 28,828 | Common Stock |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 99,009 | 99,009 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 20,147 | 20,147 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 14,184 | 28,369 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 14,184 | 33,546 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 11,338 | 11,338 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 11,338 | 40,438 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 4,861 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 4,861 | 41,745 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 4,446 | 29,100 | - | 14.5 | 64,511 | Common Stock |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 4,294 | 44,515 | - | 0 | Common Stock | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 4,294 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 3,554 | 36,884 | - | 14.5 | 51,569 | Common Stock |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 1,524 | 40,221 | - | 14.5 | 22,113 | Common Stock |
| Organon & Co. | Daniel Karp | Executive VP, Corp. Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 1,346 | 43,169 | - | 14.5 | 19,530 | Common Stock |
| AlTi Global Inc (Class A) | Daniel Karp | Director | Sale of securities on an exchange or to another person at price $ 9.50 per share. | 20 Jan 2023 | 12,500 | 12,500 | - | 9.5 | 118,750 | Class A Common Stock |
| Spectrum Brands Holdings Inc | Daniel L. Karpel | VP, Corporate Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2021 | 1,220 | 2,853 (0%) | 0% | 0 | Common Stock | |
| Spectrum Brands Holdings Inc | Daniel L. Karpel | VP, Corporate Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.97 per share. | 06 Dec 2021 | 287 | 1,633 (0%) | 0% | 100.0 | 28,691 | Common Stock |